Akari Therapeutics announced that the U.S. Food and Drug Administration has allowed on December 29, 2016, its investigational new drug application (IND) for the clinical development of Coversin™ in patients with PNH. The FDA's allowance of the IND permits the company to expand its clinical program for the development of Coversin in PNH to the United States. The company has one currently treated eculizumab resistant PNH patient who has been on Coversin for approximately 11 months pursuant to an approved clinical protocol in the Netherlands and plans to open this ongoing Phase II trial of Coversin in eculizumab resistant PNH in the United States. The objectives of this clinical trial are to determine the safety and efficacy of Coversin in patients with proven resistance to eculizumab due to complement C5 polymorphisms. These patients are entered into an open label protocol where safety and efficacy are measured on an ongoing basis. Data from patients in this trial will be presented at future scientific forums.  Akari also has an ongoing Phase II trial in Europe in patients with PNH without polymorphism with data expected in the first quarter of 2017.